Figure 2.

Serum cortisol response to Synacthen 250 µg in patients 3 months after COVID-19 (n = 70). (A) Individual responses of serum cortisol at 30 and 60 minutes after an IV bolus of 250 µg of Synacthen in patients ≥3 months after presentation with COVID-19 are presented. (B) Individual responses in change in serum cortisol from baseline at 30 and 60 minutes after an IV bolus of 250 µg of Synacthen in patients assessed ≥3 months after presentation with COVID-19 are presented. (C) Mean and SD change in cortisol from baseline (nmol/L) after an IV bolus of 250 µg of Synacthen in patients recovering from COVID-19 by WHO Disease Severity (mild, n = 12 represented by green symbols and line; moderate, n = 30, represented by orange symbols and lines; severe, n = 21, represented by red symbols and line; critical, n = 7, represented by purple symbols and line). (D) Mean (error bars show SD) change in cortisol from baseline (nmol/L) after Synacthen 250 µg in patients recovering from COVID-19 by level of care required: community care (n = 16), represented by blue symbols and line; hospitalized and not requiring ventilatory support (n = 45), represented by red symbols and lines; ventilatory support required (n = 9), represented by black symbols and lines. (E) Mean and SD change in cortisol from baseline (nmol/L) after Synacthen 250 µg in patients recovering from COVID-19 by antibody status as determined by Abbott Architect IgG to SARS-CoV-2 (detected, n = 44, represented by blue symbols and lines; not detected/indeterminate, n = 26, represented by red symbols and lines).